Leo Pharma seeks acquisitions worth up to $800 million before IPO
Updated
Updated · Bloomberg · May 5
Leo Pharma seeks acquisitions worth up to $800 million before IPO
6 articles · Updated · Bloomberg · May 5
Chief executive Christophe Bourdon said the Danish skin-disease drugmaker has backing and capacity for more deals after buying gene therapy company Replay last week.
The Replay purchase was Leo Pharma's third acquisition in 16 months, underscoring a faster expansion strategy as it prepares for a stock market listing.
The company is using dealmaking to broaden its pipeline and strengthen its position ahead of an initial public offering.
How will a preclinical gene therapy asset boost Leo Pharma's 2026 IPO valuation?
What is driving European pharma's multi-million dollar shopping spree for US biotech?
Can a novel virus-based gene therapy finally cure devastating genetic skin diseases?